Scientific article

Sildenafil for the treatment of pulmonary hypertension in children

Published inExpert review of cardiovascular therapy, vol. 12, no. 10, p. 1157-1184
Publication date2014

Pulmonary hypertension, including pulmonary arterial hypertension (PAH), is a serious disease in children, but few clinical studies have been conducted to evaluate treatment regimens in this population. Currently, treatment of children with PAH is mostly based on clinical studies conducted in adults and a few dedicated pediatric studies. Sildenafil, a phosphodiesterase type 5 inhibitor, has an established efficacy and safety profile for the treatment of adults with PAH. In May 2011, sildenafil received approval for the treatment of pediatric patients aged 1-17 years in the EU; however, pediatric use is not approved in the USA. This systematic literature review summarizes the clinical data available on the use of sildenafil to treat children with PAH and pulmonary hypertension.

Citation (ISO format)
BEGHETTI, Maurice, WACKER BOU PUIGDEFABREGAS, Julie Caroline, MERALI, Sausan. Sildenafil for the treatment of pulmonary hypertension in children. In: Expert review of cardiovascular therapy, 2014, vol. 12, n° 10, p. 1157–1184. doi: 10.1586/14779072.2014.958077
Main files (1)
Article (Published version)
ISSN of the journal1477-9072

Technical informations

Creation05/11/2015 12:52:00 PM
First validation05/11/2015 12:52:00 PM
Update time03/14/2023 11:18:19 PM
Status update03/14/2023 11:18:19 PM
Last indexation01/16/2024 6:03:11 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack